Business News • PR NewsWire • ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma

ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma

ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma

LEUVEN, Belgium, January 17, 2017 /PRNewswire/ -- ONCURIOUS NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, today announces that the European Commission has confirmed the orphan drug designation for TB-403...

View More : http://www.prnewswire.com/news-releases/oncurious-nv-announces-european-commission-confirmed-orphan-medicinal-product-de...

Releted News by prnewswire

"CHI-BA+BERRY", New Strawberry Variety Developed in Chiba Prefecture, Makes Its Debut

True Costs Of Foreclosure, Property Abandonment Extend Across Neighborhoods And Communities

Noom's Platform is the First to Offer Spanish Diabetes Prevention and Healthy Weight Management Programs to Help Address the Growing Prevalence of Type 2 Diabetes and Obesity Among Hispanic Americans